Exhibit 99.1

Oncology Leadership in Pretargeted Radioimmunotherapy Platform and Antibody - based Therapies January 2024 Disclaimer Statements in this presentation about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, constitute “forward - looking statements” within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securities Exchange Act of 1934 . Such statements include, but are not limited to, statements about the Company’s growth prospects and expectations related thereto ; expectations with respect to the Company’s financial expectations, including the Company’s 2023 operating expense, cash burn and DANYELZA net product revenue guidance, and the Company’s estimated cash runway and sufficiency of cash resources and related assumptions ; the Company’s ability to deliver value ; expectations with respect to the achievement of milestones and the timing thereof ; implied and express statements regarding the future of the Company’s business, including with respect to expansion and its goals ; the Company’s plans and strategies, development, commercialization and product distribution plans, including potential partnerships ; expectations with respect to the Company’s products and product candidates, including potential territory and label expansion of DANYELZA and the potential market opportunity related thereto and potential benefits thereof, and the potential of the SADA Technology and potential benefits and applications and the timing thereof ; SADA’s potential to be an industry game - changer ; expectations with respect to current and future clinical and pre - clinical studies and the Company’s and its partners’ research and development programs, including with respect to timing and results ; expectations related to the timing of the initiation and completion of regulatory submissions ; additional product candidates and technologies ; expectations regarding collaborations or strategic partnerships and the potential benefits thereof ; expectations related to the use of cash and cash equivalents, and the need for, timing and amount of any future financing transaction ; expectations with respect to the Company’s future financial performance ; and other statements that are not historical facts . Words such as ‘‘anticipate,’’ ‘‘believe,’’ “contemplate,” ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ “hope,” ‘‘intend,’’ ‘‘may,’’ ‘‘might,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘should,’’ ‘‘target,’’ “will”, ‘‘would’’, “guidance,” and similar expressions are intended to identify forward - looking statements, although not all forward - looking statements contain these identifying words . The Company’s product candidates and related technologies are novel approaches to cancer treatment that present significant challenges . Actual results may differ materially from those indicated by such forward - looking statements as a result of various factors, including but not limited to : risks associated with the Company’s financial condition and need for additional capital ; the risks that actual results of the Company’s restructuring plan and revised business plan will not be as expected ; risks associated with the Company’s development work ; cost and success of the Company’s product development activities and clinical trials ; the risks of delay in the timing of the Company’s regulatory submissions or failure to receive approval of its drug candidates ; the risks related to commercializing any approved pharmaceutical product including the rate and degree of market acceptance of product candidates ; development of sales and marketing capabilities and risks associated with failure to obtain sufficient reimbursement for products ; the risks related to the Company’s dependence on third parties including for conduct of clinical testing and product manufacture ; the Company’s ability to enter into new partnerships and to maintain existing partnerships ; the risks related to government regulation ; risks related to market size and approval, risks associated with protection of the Company’s intellectual property rights ; risks related to employee matters and managing growth ; risks related to the Company’s common stock ; risks associated with macroeconomic conditions, including the conflict between Russia and Ukraine and sanctions related thereto, the state of war between Israel and Hamas and the related risk of a larger regional conflict, inflation, increased interest rates, uncertain global credit and capital markets and disruptions in banking systems ; the completion of financial closing procedures, final audit adjustments and other developments that may arise that would cause the Company’s expectations with respect to the Company’s 2023 guidance to differ, perhaps materially, from the financial results that will be reflected in the Company’s audited consolidated financial statements for the fiscal year ended December 31 , 2023 ; and other risks and uncertainties affecting the Company including those described in the “Risk Factors” section included in the Company’s Annual Report on Form 10 - K for the fiscal year ended December 31 , 2022 , the Company’s Quarterly Report on Form 10 - Q for the quarter ended September 30 , 2023 and future filings and reports by the Company . Any forward - looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update any forward - looking statement, whether as a result of new information, future events or otherwise . This presentation includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties or us . Industry publications and third - party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information . All of the market data used in this presentation involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates . While we believe these industry publications and third - party research, surveys and studies are reliable, we have not independently verified such data . The industry in which we operate is subject to a high degree of uncertainty, change and risk due to a variety of factors, which could cause results to differ materially from those expressed in the estimates made by the independent parties and by us . 2 Strongly Positioned to Drive Future Value 3 Novel Platforms in Development S elf - A ssembly D is A ssembly (“SADA”) Pretargeted Radioimmunotherapy Platform (“PRIT ”) Monoclonal Antibodies GD2 - SADA Phase I Part A Data Readout CD38 - SADA Phase I Study Initiation MSK Data Readout of Phase II Osteosarcoma Trial Anticipated Anticipated 2024 Milestones Commercial Leverage DANYELZA ( naxitamab - gqgk ) Anti - GD2 Antibody Marketed for R/R High - Risk Neuroblastoma Capital Efficiency Independent Commercial - S tage Biotech C ompany with Cash of ~$87 million * Financial Runway into 2027 Maintain FY2023 Guidance * As of September 30, 2023

複数の付加価値カタリストを有する重点パイプラインの推進 4 試験 治療領域 前臨床第Ⅰ相第Ⅱ相/ピボタル承認試験 スポンサーステータス リードプログラム 201 再発/難治性の高リスク神経芽腫（小児） 米国FDA承認 Naxitamab - gqgk (Anti - GD2) 12 - 230 再発/難治性の高リスク神経芽腫（小児） 米国FDA承認 BCC018 高リスク神経芽腫におけるフロントライン導入療法FDA 承認 BCC018 高リスク神経芽腫（小児）におけるフロントライン導入療法 2024年第2四半期にランダム化試験を実施予定 15 - 096 再発二次治療骨肉腫 2024年第4四半期にMSKデータリードアウトを予定 17 - 251 再発/難治性高リスク神経芽腫に対する化学免疫療法 試験終了 SADA（放射免疫療法） 1001 GD2 - SADA：固形がん（SCLC、悪性黒色腫、肉腫） 最初の治療コホート 1201 CD38 - SADA: 非ホジキンリンパ腫 2024年にフェーズⅠ開始予定 初期プログラム SADA（放射免疫療法） GD2 - SADA：神経芽腫 2024年にIND申請予定 HER2 - SADA 2025年にIND申請予定 B7H3 - SADA 2025年にIND申請予定 DANYELZA ( naxitamab - gqgk ) 確定試験 DANYELZA ( naxitamab - gqgk )

5 新規のSADA前標的放射免疫療法技術プラットフォーム 現在のラジオファーマの課題は患者ケアに悪影響を及ぼす 6 インフラと製造 医師が参加する管理施設 継続する医薬品不足 より簡便で使いやすいソリューションが医師と患者にとって大いに必要である

SADAの新しいプレターゲット2ステップアプローチは、業界のゲームを変える可能性がある * 7 SADAプラットフォームの潜在能力 x プレターゲット腫瘍は、毒性を最小限に抑え、未結合タンパク質の迅速な除去を促進する可能性がある x 短いT1/2アイソトープを使用できる可能性がある x 大きな輸液センターで腫瘍内科医が1回分のタンパク質を投与することで、より広範な部位を選択できる可能性がある x COGSが改善される可能性がある 従来の放射線免疫療法 全身的な高毒性のリスクがある シングルアイソトープでは、薬剤不足/供給の問題が発生しやすい。核医学の免許を持つ放射線科医がいる限られた投与施設 特定のインフラと製造のために高額な投資が必要 * 開発と承認が成功することを待つ。

Self - A ssemble D is A ssembly (SADA) Technology: 腫瘍標的に対する高い親和性と血流からの迅速なクリアランス SADAドメインは、タンパク質が濃度に応じてサイズを変えられるように独自に選択されたもの Santich et al.Clin Canc Res 2020 Self - A ssembled Tetramer ~200 kDa Strong Tumor B inding D is A ssembled Monomer < 70kDa Rapid Clearance Anti - Tumor Anti - DOTA P53 Linker 8 SK0 従来のGD2抗体の血流中での持続性は、実質的な不要な曝露と毒性の増加をもたらす 9 Santich et al.

23 Company Takeaways